SERB

What SERB does

SERB Pharmaceuticals is a Brussels-headquartered, Luxembourg-domiciled (SERB S.à.r.l.) global specialty pharmaceutical company founded in 1950 that has operated for over 30 years in the niche of rare diseases, emergency medicines, medical countermeasures, and antidotes. The company commercializes a portfolio of 70+ essential medicines through direct sales operations in 18 countries and distribution networks serving healthcare providers in over 100 countries. Its core product franchises include Idefirix (imlifidase) — an enzyme therapy licensed-in for €115M from Hansa Biopharma in May 2026 for highly sensitized kidney transplant patients across Europe and MENA; FIRDAPSE (amifampridine) — a Lambert-Eaton myasthenic syndrome treatment licensed to Catalyst Pharmaceuticals in the US (with patent exclusivity protected through January 2035); and ThyroSafe 130mg potassium iodide tablets, now commercially available in the US for thyroid protection during nuclear emergencies.

The company generates revenue primarily through pharmaceutical product sales across three channels: direct enterprise sales to healthcare systems and first responders, government emergency preparedness stockpiling contracts, and out-licensing arrangements such as the FIRDAPSE/Catalyst partnership. SERB's customer base spans hospitals, clinics, government health agencies, emergency medical services, and non-profit healthcare organizations. Key subsidiary brands include BTG and Veriton, retained from prior acquisitions (BTG Specialty Pharmaceuticals acquired 2020; Veriton Pharma acquired 2020). The company is privately held with no public ticker or identified parent organization, and reports 500+ dedicated employees worldwide.

SERB's competitive positioning relies on an integrated specialty pharma platform capable of acquiring, developing, manufacturing, and commercializing niche medicines that larger pharmaceutical companies typically deprioritize. Its value proposition centers on regulatory expertise in fragmented international markets, validated quality processes (accreditations documented separately), and decades-long relationships with government preparedness and healthcare system buyers. Recent strategic moves in 2026 — including the €115M Idefirix acquisition, the US ThyroSafe launch, and US Board expansion with Dr. Peter C. Adamson — signal an offensive push into US and broader European/MENA specialty pharma markets, supported by sustained M&A activity and licensing transactions.

Name

SERB

Legal name

SERB S.à.r.l.

Website

https://serb.eu

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

251–500 employees

Short description

SERB Pharmaceuticals is a Brussels-based specialty pharmaceutical company (founded 1950) that commercializes 70+ rare disease, emergency medicine, and antidote products across 100+ countries through direct sales and distribution networks serving healthcare providers, first responders, and government preparedness agencies.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Specialty pharmaceuticals
• Emergency medicines
• Medical countermeasures
• Rare disease treatments
• Antidote portfolio

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SERB generates revenue through the sale of specialty pharmaceutical products including emergency medicines, medical countermeasures, and antidotes. The company commercializes a portfolio of 70+ medicines directly in 18 countries and supplies to over 100 countries globally.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels3 records

Core offering

SERB Pharmaceuticals is a global specialty pharmaceutical company that develops, manufactures, and commercializes a portfolio of 70+ essential medicines, including emergency medicines, medical countermeasures, and the world's leading portfolio of antidotes for rare diseases and medical emergencies. The company serves healthcare providers, first responders, emergency preparedness agencies, and non-profit organisations across more than 100 countries via direct sales in 18 countries and through licensing partnerships.

Product overview

SERB Pharmaceuticals is a global specialty pharmaceutical company offering a broad portfolio of 70+ medicines for rare diseases and medical emergencies. The company provides medical countermeasures, antidotes, and critical care medicines to healthcare providers in over 100 countries. Key products include Idefirix (imlifidase) for kidney transplant patients, FIRDAPSE (amifampridine) for rare neuromuscular conditions, and ThyroSafe potassium iodide tablets for nuclear emergency preparedness. The portfolio is delivered through healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.

Differentiator

Problem solved

Functional benefit

Brands

• BTG: BTG® is a registered trademark of Protherics Medicines Development Ltd.
• Veriton

Products and services

• Idefirix (imlifidase) Enzyme therapy for highly sensitized kidney transplant patients that breaks down antibodies that would otherwise reject the donor organ, enabling kidney transplantation.
• FIRDAPSE (amifampridine) 10 mg tablets Medication for Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular disease. Distributed by SERB S.A. and licensed to Catalyst Pharmaceuticals for US commercialization, with patent protection preventing generic launch before January 2035.
• ThyroSafe 130mg Potassium Iodide Tablets Potassium iodide tablets for thyroid protection during radiation/nuclear emergencies, available in a 130 mg dose in the US market.
• Emergency Medicines and Antidote Portfolio Portfolio of 70+ essential medicines including emergency medicines, medical countermeasures, and the world's leading portfolio of antidotes, delivered via healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.

Quantifiable outcome

• Serving healthcare providers in over 100 countries
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Hansa Biopharma ABcoreStrategic or Co-development Partner · 19 May 2026SERB Pharmaceuticals entered into a €115 million exclusive licensing agreement with Hansa Biopharma for the development and commercialisation of Idefirix (imlifidase) in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA regions. SERB will acquire exclusive rights, with Hansa receiving €110 million upfront payment and €5 million upon EMA filing acceptance. The transaction closed on July 1, 2026.
• Catalyst PharmaceuticalscoreStrategic or Co-development Partner · 7 May 2026SERB S.A. serves as licensor to Catalyst Pharmaceuticals for FIRDAPSE (amifampridine) 10 mg tablets. Settled patent litigation with Hetero Labs ensuring generic version not marketed before January 2035. Catalyst was later acquired by Angelini Pharma for $4.1 billion in 2026.
• Hetero Labs Ltd.minorStrategic or Co-development Partner · 7 May 2026Hetero Labs attempted to launch generic version of FIRDAPSE. Settlement agreement reached prohibiting Hetero from marketing generic version in US before January 2035, pending FDA approval. All ongoing patent litigation terminated.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Endo International: US specialty pharma with branded specialty care, sterile injectables, and generic injectable portfolios; comparable in hospital-channel distribution and specialty therapeutics focus, although broader in scope.
• Almirall: European specialty pharma with a portfolio of dermatology, neurology, and specialty care products — overlaps with SERB in specialty therapeutics distribution across European healthcare systems.
• Alexion Pharmaceuticals (AstraZeneca Rare Disease): Rare-disease specialty pharma now part of AstraZeneca. Overlaps with SERB in rare-disease commercialization (e.g., complement-mediated and neurologic conditions) and in delivering high-value therapies through specialty distribution.

Direct peers

• Emergent BioSolutions: US-listed specialty pharma focused on medical countermeasures, vaccines, and antidotes (including CBRN products) sold to governments and first responders — the closest publicly listed analog to SERB's antidote and emergency preparedness portfolio.
• Vifor Pharma: Specialty pharma with a portfolio in iron deficiency, nephrology, and rare conditions. Now part of CSL but historically comparable as a European specialty pharma with hospital-channel distribution.
• Swedish Orphan Biovitrum (Sobi): European-headquartered rare-disease specialty pharma with a portfolio of niche, high-value therapeutics — comparable in scale, specialty distribution model, and focus on underserved patient populations.
• Mallinckrodt Pharmaceuticals: Specialty pharma with established brands in antidotes, critical care, and rare diseases. Comparable in therapeutic focus on hospital-administered specialty medicines and niche emergency indications.
• Hansa Biopharma: Biopharma developing Idefirix (imlifidase) for kidney transplantation — directly linked to SERB as the licensor of European and MENA rights in the €115M 2026 deal; comparable in rare/ultra-rare specialty biotech positioning.
• Catalyst Pharmaceuticals: US specialty pharma commercializing FIRDAPSE under license from SERB; an existing commercial counterparty whose rare-disease commercialization model for LEMS is closely aligned with SERB's specialty pharma approach.
• Recordati: European specialty pharma focused on rare diseases and specialty care products distributed through established healthcare networks — directly comparable in business model and geographic mix to SERB.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/serb_pharma
• LinkedInlinkedin.com/company/serb-specialty-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SERB